title: Edaravone - citicoline comparative study in acute ischemic stroke (ECCS-AIS).
abstract: BACKGROUND
  Two new neuro-protective agents, Edaravone and Citicoline were recently found to be beneficial in acute ischemic stroke (AIS). But there is no study to compare these two agents on same protocol in AIS. This study was aimed to compare these two neuroprotective agents in AIS.
  
  
  METHODS
  All patients of age more than 18 years who presented within 24 hours of acute ischemic stroke were randomly treated with Edaravone (group E), Citicoline (group C) or none (group N) with other standard treatment of AIS. Modified Rankin Scale (MRS) and National Institute of Health Stroke Scale (NIHSS) were recorded on admission and at 3 months. Analysis was done using Anova t test to find out significant difference in outcome at 3 months. P value of < or = 0.05 was labeled as significant.
  
  
  RESULTS
  Mean MRS and NIHSS scores at 3 months were lowest in group E (p = 0.000), suggestive of better outcome in this group. After application of severity scale, 15 patients (68.1%) in group-E, 14 (58.3%) in group C and 18 (72%) in group N had moderate to severe stroke (NIHSS of more than 10). When the patients of moderate to severe stroke were analyzed separately at 3 months, patients in group E (mean 4.46 +/- 3.52) had significantly (p = 0.00) better outcome in comparison to group C (mean 10.28 +/- 7.93) and group N (mean 9.38 +/- 6.44).
  
  
  CONCLUSIONS
  Edaravone was found to be associated with better neurological outcome at 3 months. Citicoline's role as a neuroprotective agent however remains controversial in acute ischaemic stroke.
authors.affiliation: Department of General Medicine, HIHT University, Swami Ram Nagar, Doiwala, Dehradun.
authors.forename: Manish
authors.initials: M
authors.lastname: Mitta
authors.forename: Deepak
authors.initials: D
authors.lastname: Goel
authors.forename: Krishan K
authors.initials: KK
authors.lastname: Bansal
authors.forename: Prashant
authors.initials: P
authors.lastname: Puri
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002545:Brain Ischemia / Q000150:complications*; D003566:Cytidine Diphosphate Choline / Q000627:therapeutic use*; D000077553:Edaravone; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018696:Neuroprotective Agents; D003566:Cytidine Diphosphate Choline; D000077553:Edaravone; D000983:Antipyrine